Published in: Lancet Oncology
Authors: Ahmed A Sultan, Waseem Jerjes, Kristian Berg, Anders Høgset, Charles A Mosse, Rifat Hamoudi, Zaid Hamdoon, Celia Simeon, Dawn Carnell, Martin Forster, Colin Hopper
Photochemical internalization with bleomycin was studied in a Phase 1, first-in-man trial for local recurrent, advanced, or metastatic H&N cancer. Modulight laser was used for activation of TPCS2a photosensitizer at the surface of the target tumor. 12 patients completed the 3-month follow-up, with maximum tolerated dose of TPCS2a being established to 1.0 mg/kg.
